Cardiovascular Phase 2 Deal Benchmarks (2026)

Median upfront of $505M with total deal values reaching $3.4B.

Median Upfront

$505M

Total Deal Value

$2.5B

Royalty Range

8.8%–17.6%

Territory Multiplier

Understanding Cardiovascular Deal Benchmarks at Phase 2

Phase 2 Cardiovascular licensing deals command a median upfront payment of $505M, with values ranging from $277M at the low end to $724M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the cardiovascular therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.6B to $3.4B, with a median of $2.5B. Royalty rates for cardiovascular assets at this stage typically fall between 8.8% and 17.6% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

Year	Licensor	Licensee	Upfront	Total Value	Deal Type
2024	BridgeBio Pharma	Astellas Pharma	$400M	$1.7B	licensing
2024	Alnylam Pharmaceuticals	Roche	$310M	$2.2B	licensing
2023	Cytokinetics	Royalty Pharma	$500M	$2.0B	licensing
2023	Ionis Pharmaceuticals	Novartis	$150M	$900M	licensing
2023	Tenaya Therapeutics	Roche	$60M	$1.2B	collaboration
2024	Verve Therapeutics	Eli Lilly	$60M	$560M	option
2023	Rocket Pharmaceuticals	N/A (standalone)	$0M	$650M	licensing
2023	CRISPR Therapeutics	Vertex Pharmaceuticals	$100M	$900M	collaboration
2024	Cardiol Therapeutics	N/A (standalone)	$0M	$250M	licensing
2022	MyoKardia	BMS	$13.1B	$13.1B	acquisition

PRO

See All Comparable Deals

View 10 comparable Cardiovascular transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 2 Cardiovascular deals?

The median upfront payment for Phase 2 Cardiovascular licensing deals is $505M, based on our analysis of comparable transactions. Values range from $277M for early-stage or less differentiated assets up to $724M for premium programs with strong clinical data or first-in-class mechanisms.

How does Global territory affect Cardiovascular deal value?

Global rights carry a 1x multiplier relative to base deal economics. This means global cardiovascular deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 2 Cardiovascular licensing?

Royalty rates for Phase 2 cardiovascular assets typically range from 8.8% to 17.6% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$51M upfront

Cardiovascular · Preclinical · Global

$131M upfront

Cardiovascular · Phase 1 · Global

$1.4B upfront

Cardiovascular · Phase 3 · Global

$3.8B upfront

Cardiovascular · Approved · Global

$258M upfront

Oncology · Phase 2 · Global

$232M upfront

Neurology/CNS · Phase 2 · Global

$547M upfront

Immunology · Phase 2 · Global

$589M upfront

Metabolic/Obesity · Phase 2 · Global

Explore More

All Cardiovascular Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Cardiovascular · Phase 2

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Cardiovascular Phase 2 Deal Benchmarks (2026). Retrieved from https://calculator.ambrosiaventures.co/data/cardiovascular-phase-2-deals-global

HTML

<a href="https://calculator.ambrosiaventures.co/data/cardiovascular-phase-2-deals-global">Cardiovascular Phase 2 Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$277M	$505M	$724M
Total Deal Value	$1.6B	$2.5B	$3.4B
Royalty Rate	8.8%	—	17.6%